136 related articles for article (PubMed ID: 34919735)
1. Detection of folate receptor-positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer.
Wu Q; Zheng H; Gu J; Cheng Y; Qiao B; Wang J; Xiong L; Sun S; Wu Z; Bao A; Tong Y
J Clin Lab Anal; 2022 Jan; 36(1):e24180. PubMed ID: 34919735
[TBL] [Abstract][Full Text] [Related]
2. Folate-receptor-positive circulating tumor cells as an efficacious biomarker for the diagnosis of small pulmonary nodules.
Xue Y; Cong W; Xie S; Shu J; Feng G; Gao H
J Cancer Res Ther; 2018; 14(7):1620-1626. PubMed ID: 30589049
[TBL] [Abstract][Full Text] [Related]
3. Ligand-targeted polymerase chain reaction for the detection of folate receptor-positive circulating tumour cells as a potential diagnostic biomarker for pancreatic cancer.
Cheng H; He W; Yang J; Ye Q; Cheng L; Pan Y; Mao L; Chu X; Lu C; Li G; Qiu Y; He J
Cell Prolif; 2020 Sep; 53(9):e12880. PubMed ID: 32707596
[TBL] [Abstract][Full Text] [Related]
4. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
5. Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.
Zhou Q; Geng Q; Wang L; Huang J; Liao M; Li Y; Ding Z; Yang S; Zhao H; Shen Q; Pan C; Lou J; Lu S; Chen C; Luo Q
EBioMedicine; 2019 Mar; 41():236-243. PubMed ID: 30872130
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic Value of Folate Receptor-positive Circulating Tumor Cell in Lung Cancer: A Pilot Study].
Lian H; Ding Z; Yuan D; Ma J; Qin J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):813-820. PubMed ID: 27978866
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
8. The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.
Xu Y; Li Q; Lin Z; Lin Y
Clin Respir J; 2023 May; 17(5):374-383. PubMed ID: 36977421
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of colorectal cancer based on folate receptor-positive circulating tumor cell analysis: a retrospective cohort study.
Wei ZJ; Zhou BC; Wang GX; Han WX; Li YX; Xu AM
Int J Clin Oncol; 2024 Feb; 29(2):149-158. PubMed ID: 38112831
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer.
Wang L; Wu C; Qiao L; Yu W; Guo Q; Zhao M; Yang G; Zhao H; Lou J
J Cancer; 2017; 8(1):104-110. PubMed ID: 28123603
[No Abstract] [Full Text] [Related]
11. The role of folate receptor-positive circulating tumor cell analysis in the diagnosis of colorectal cancer: a retrospective cohort study.
Yan S; Guo W; Liu Y; Li K; Wang W
Int J Clin Oncol; 2022 Mar; 27(3):538-544. PubMed ID: 35043284
[TBL] [Abstract][Full Text] [Related]
12. Validation of the diagnostic efficiency of folate receptor-positive circulating tumor cells in lung cancers: a prospective observational study.
Liu J; Han M; Huang H
Transl Cancer Res; 2019 Aug; 8(4):1242-1248. PubMed ID: 35116866
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Folate Receptor-Positive Circulating Tumor Cell Level Is a Prognostic Factor of Long Term Outcome in Non-Small Cell Lung Cancer Patients.
Li H; Li B; Pan Y; Zhang Y; Xiang J; Zhang Y; Sun Y; Yu X; He W; Hu H
Front Oncol; 2020; 10():621435. PubMed ID: 33585249
[TBL] [Abstract][Full Text] [Related]
14. A preliminary study of the clinical significance of folate receptor-positive circulating tumor cell in the management of hepatobiliary-pancreatic cancers.
He YG; Zheng L; Gao MF; Tang YC; Li YM; Yu KH; Li J; Huang XB
Transl Cancer Res; 2020 Nov; 9(11):6700-6709. PubMed ID: 35117280
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
16. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.
Matuschek C; Bölke E; Lammering G; Gerber PA; Peiper M; Budach W; Taskin H; Prisack HB; Schieren G; Orth K; Bojar H
Eur J Med Res; 2010; 15(7):277-86. PubMed ID: 20696638
[TBL] [Abstract][Full Text] [Related]
17. The utility of folate receptor-positive circulating tumor cell in cancer diagnosis in the elderly population.
Li N; Zhong D; Chen H; Huang T; Hou P; Zhang Y; Chen F; Wang X; Zhang H
Cancer Manag Res; 2019; 11():4097-4107. PubMed ID: 31190982
[No Abstract] [Full Text] [Related]
18. Preoperative Folate Receptor-Positive Circulating Tumor Cells Are Associated With Occult Peritoneal Metastasis and Early Recurrence in Gastric Cancer Patients: A Prospective Cohort Study.
Zeng CDD; Jin CC; Gao C; Xiao AT; Tong YX; Zhang S
Front Oncol; 2022; 12():769203. PubMed ID: 35425708
[TBL] [Abstract][Full Text] [Related]
19. The combination of folate receptor-positive circulating tumor cells and serum tumor markers suggests a histological diagnosis of lung cancer.
Lv X; Wu S; Xu X; Wu L; Chang N; Zhang J; Ti X
J Thorac Dis; 2022 Jan; 14(1):158-168. PubMed ID: 35242377
[TBL] [Abstract][Full Text] [Related]
20. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
